AZD4547 + tislelizumab

AZD4547 + tislelizumab is an investigational combination therapy comprising AZD4547 (also known as ABSK091 or fexagratinib), a highly potent and selective small molecule inhibitor of fibroblast growth factor receptor (FGFR) subtypes 1, 2, and 3, and tislelizumab (BGB-A317), a humanized IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1). AZD4547 inhibits tumor growth driven by FGFR aberrations, while tislelizumab releases immune inhibition by blocking PD-1, thereby facilitating T cell-mediated antitumor responses. Both agents target critical pathways in oncology: AZD4547 for tumors with FGFR alterations, and tislelizumab for various cancers progressing on prior therapies or expressing PD-L1. This combination is being developed primarily for metastatic urothelial cancer (mUC), especially in platinum-ineligible or chemotherapy-refractory patients, leveraging the complementary mechanisms of precision oncology (FGFR inhibition) and immuno-oncology (PD-1 blockade)[1][3][5].

Other names

Fexagratinib + tislelizumab